Compare AU
Compare VISM vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard MSCI International Small Companies Index ETF (VISM) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VISM | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 270 | 63 |
Median incremental investment | $1,211.45 | $990.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,444.91 | $1,955.77 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
VISM | DRUG | |
|---|---|---|
Strategy | Vanguard MSCI International Small Companies Index ETF aims to track the returns and performance of the MSCI World ex-Australia Small Cap Index before considering fees, expenses, and tax. It tracks the performance of the index with dividends reinvested. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Reliance Steel & Aluminum Co. (0.20 %) United Therapeutics Corp. (0.20 %) Axon Enterprise Inc. (0.19 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Industrials (19.35 %) Financials (14.55 %) Consumer Discretionary (12.64 %) | Other (77.25 %) Communication Services (33.53 %) Health Care (22.59 %) |
Top 3 countries | United States (62.44 %) Japan (12.99 %) United Kingdom of Great Britain and Northern Ireland (5.56 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.32 % | 0.57 % |
Key Summary
VISM | DRUG | |
|---|---|---|
Issuer | Vanguard | BetaShares |
Tracking index | MSCI World ex AU Small Cap | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.32 % | 0.57 % |
Price | $62.69 | $7.61 |
Size | N/A | $166.049 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.21 % | 1.89 % |
Market | ASX | ASX |
First listed date | 13/11/2018 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VISM | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 270 | 63 |
Median incremental investment | $1,211.45 | $990.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,444.91 | $1,955.77 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
VISM | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VISM | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |